Bilirakis Voices Concerns About New FDA Drug Regulations

"Generic drugs are effective alternatives that offer a more affordable option for an individual who wants to save money. FDA's new regulations change drug labeling from a top down, synthesized approach, to one that will cause confusion for drug companies and consumers," Bilirakis said. "The results of these regulations for generic drug companies are clear; they will be forced to spend more money protecting themselves from frivolous lawsuits and increased costs. It is my concern this will dramatically increase prices for consumers that rely on generic drugs as a less expensive, successful alternative for their medical needs. There is no public health benefit."

On January 22, 2014, Congressman Bilirakis signed a letter to FDA Commissioner Margaret Hamburg, opposing these regulations from the FDA. To see the entirety of Congressman Bilirakis' remarks, click here.